INTERVIEW: Chipscreen CEO Bets Big On Chinese Innovation
This article was originally published in PharmAsia News
Executive Summary
When initial funding burned through and co-founders bailed out, Chipscreen CEO Lu Xianping faced the biggest challenge of his career. A firm belief in scientific evidence and an unwavering confidence in China-originated innovation helped him launch chidamide, a true made in China drug for a rare blood cancer, Lu told PharmAsia News in an exclusive interview.